|
|
4-6 Rue Du Dauphine
Vaulx-en-Velin, 69120 France
phone:33 4 72 15 31 50
fax:+33 (0) 4 72 15 31 51
|
|
| Symbol |
EDAP |
| Exchange |
Nasdaq |
| Founded |
1979 |
| Employees |
144 |
|
|
| www.edap-tms.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Minimally invasive medical devices for the treatment of urological diseases. |
|
| Management |
| Marc Oczachowski, Chief Executive Officer; Eric Soyer, Chief Financial Officer; Philippe Chauveau, Chairman of the Board of Directors; Pierre Beysson , Karim Fizazi , Karim Fizazi |
| |
|
|
|
|
|
|
| Recent Results |
| For the 12 months ended 12/31/05, the company reported total revenues of EUR 20.8 million, down from EUR 22.2 million in 2004. The company reported a loss of EUR 941,000 for 2005, compared to a loss of EUR 1.1 million in 2004. |
| |
|
|
|
|
| Keywords |
| ultrasound, urological, urology, urine, urinary tract, cancer, Urology, prostate, urinary, bladder, erectile cancer, tumors |
|
|
|
| Description |
|
EDAP TMS S.A. develops, manufactures, markets and distributes a portfolio of minimally invasive medical devices primarily for the treatment of urological diseases. The groups consists of two companies: EDAP S.A., the HIFU division, dedicated to the development and marketing of HIFU technology and TMS S.A., the UDS division, specialized in providing urology devices and services. |
|
| Products / Services |
The company's products include: Ablatherm(tm), a HIFU minimally-invasive devices for treatment of localized prostate cancer, medical equipment for treatment of urinary tract stones, and devices for the non-surgical treatment of benign prostate hyperplasia
|
|
| Market / Customers |
EDAP distributes its products in Canada, the European Union, South Korea, Russia, Australia, Japan, the Sonolith Vision, and the United States.
|
|
| Strategy |
The company believes that minimally-invasive treatments using HIFU could provide an alternative to current invasive therapies on the basis of reduced cost and minimized side effects for a number of different indications.
|
|
| Funding |
| At the end of December 2005, the company had more than EUR 8.3 million in cash. |
|
| Status |
| The company anticipates future growth to primarily be generated by the HIFU division as increasing acceptance and demand for Ablatherm-HIFU treatment continues to generate sales activity on a per procedure and equipment basis. |
|
|
|
| |
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members